Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $51K of Stock

Quang Pham, who serves as the Chairman, CEO, and Interim CFO of CVKD, recently sold 12,996 shares of the company on June 12, 2026. The shares were sold at an average price of $3.94, amounting to a total transaction value of $51,204.24. This sale is part of a series of insider transactions by Pham in June 2026.

Insider Buying and Selling at Cadrenal Therapeutics, Inc.

Quang Pham has been actively selling shares of CVKD throughout June 2026. On June 15, he sold 3,666 shares at an average price of $3.58. Earlier, on June 11, he sold 1,462 shares for $4.12 each. On June 10, a planned sale involved 3,500 shares at $4.21. Additionally, on June 9, he sold 12,992 shares at $4.06, and on June 8, another planned sale involved 5,893 shares at $4.38.

Other Institutional Activity in CVKD

Vanguard Capital Management LLC recently increased its holdings in CVKD by 45,201 shares, bringing its total to 45,201 shares valued at about $231,429. Geode Capital Management, LLC added 7,098 shares, now holding 21,626 shares worth $110,724. Vanguard Fiduciary Trust Co acquired 8,311 shares, totaling 8,311 shares valued at $42,552. BlackRock, Inc. also increased its position by 1,974 shares, now holding 5,496 shares valued at $28,140.

Cadrenal Therapeutics, Inc. Stock Up 211.2%

Shares of CVKD are trading near $3.33. Despite recent insider activity, the stock's performance continues to be closely monitored by investors. The company's market performance and valuation metrics remain a point of interest for both institutional and individual investors.

Analysts Set New Price Targets

On April 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on CVKD with a price target of $13.0. This follows previous ratings from the firm, which reiterated a 'buy' rating with a $32.0 target on May 16, 2025. Noble Financial also maintained a 'buy' rating with a $4.0 target on March 13, 2024.

Bottom Line

Quang Pham's recent sales of CVKD shares are part of a broader pattern of insider activity in early June 2026. Investors often keep an eye on such transactions for potential insights into company leadership's confidence in the stock. Meanwhile, institutional investors have been adjusting their positions, and analysts continue to express a positive outlook with maintained 'buy' ratings and varied price targets. As always, these insights are based on past activities and do not necessarily predict future performance.